News
ORXOY
2.800
NaN%
--
Orexo to host Q1 interim report presentation and Q&A session
PUBT · 1d ago
Orexo says total shares 37.2 million, total voting rights 35.3 million
Reuters · 04/01 02:00
Orexo announces annual general meeting notice to shareholders
Reuters · 03/30 10:03
Orexo proposes LTIP 2026, estimates total cost about SEK 12 million
Reuters · 03/30 10:03
Orexo AB FY2025 publishes sustainability report; greenhouse gas emissions drop 33% since 2022 baseline
Reuters · 03/27 09:36
Orexo to host investor R&D Day on amorphous drug delivery strategy
Reuters · 03/24 06:32
Orexo appoints Lisa Moore as SVP Products and Portfolio Strategy as Robert DeLuca retires
Reuters · 03/06 15:30
Invitation & Agenda: Orexo R&D Day on March 24
Barchart · 03/06 10:22
**Orexo to host R&D Day in Stockholm**
Reuters · 03/06 09:03
Orexo AB Board Converts 416,417 Class C Shares to Ordinary Shares and Transfers 416,417 Ordinary Shares Under LTIP 2023–2025
Reuters · 02/19 16:33
Orexo AB posts Q4 2025 net earnings of SEK 724.8 million after Zubsolv divestment
Reuters · 02/05 06:03
Orexo AB erzielt im vierten Quartal 2025 einen Nettoertrag aus fortgeführten Aktivitäten von -115,6 Mio. SEK, was einer Verbesserung um 35 Prozent entspricht
Reuters · 02/05 06:03
Orexo Sells Zubsolv US Business to Dexcel Pharma USA
Reuters · 12/22/2025 20:02
Orexo AB Secures BARDA Partnership for Development of OX390 Overdose Rescue Therapy
Reuters · 12/05/2025 08:00
Weekly Report: what happened at ORXOY last week (0908-0912)?
Weekly Report · 09/15/2025 09:35
Weekly Report: what happened at ORXOY last week (0901-0905)?
Weekly Report · 09/08/2025 09:37
Weekly Report: what happened at ORXOY last week (0825-0829)?
Weekly Report · 09/01/2025 09:35
Orexo AB to Present at Nordic Life Science Days Conference on Building Robust IP Strategies
Reuters · 08/29/2025 11:30
Weekly Report: what happened at ORXOY last week (0818-0822)?
Weekly Report · 08/25/2025 09:37
Weekly Report: what happened at ORXOY last week (0811-0815)?
Weekly Report · 08/18/2025 09:35
More
Webull provides a variety of real-time ORXOY stock news. You can receive the latest news about Orexo Ab through multiple platforms. This information may help you make smarter investment decisions.
About ORXOY
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.